Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

One hundred out-patients with inflammatory process of dental tissues due to tooth extraction, root abscess alveolitis and periodontitis, were randomly assigned, according to a double-blind design, to one of two treatment groups with nimesulide (200 mg/day) or oxyphenbutazone (400 mg/day). By means of a self-rating record, each patient rated his pain, difficulty of chewing, redness and swelling before starting, during and at the end of treatment. Nimesulide and oxyphenbutazone were both well tolerated and effective, but the improvements during the first and the second day of treatment were of greater magnitude in the nimesulide-treated patients. Nimesulide, being well tolerated, rapid acting and effective, could be considered as a drug of choice for the treatment of inflammatory process of dental tissues.
 ...
PMID:Nimesulide in the short-term treatment of inflammatory process of dental tissues: a double-blind controlled trial against oxyphenbutazone. 634 46

Nimesulide, 4-nitro-2-phenoxymethanesulphonanilide, a new non-steroidal anti-inflammatory drug endowed with potent anti-inflammatory, analgesic and antipyretic activities, was tested at a daily dose of 200 mg b.i.d. against Benzydamine on a double-blind basis, in a randomized trial with fifty out-patients suffering from inflammatory ear, nose and throat diseases (otitis media, sinusitis, rhinitis). Nimesulide treatment brought about an immediate and significant improvement in over-all pain, exudation, oedema and headache and produced a rapid lowering in body temperature. The recovery was more rapid and significant in patients with Nimesulide than in those with Benzydamine. The signs and symptoms under consideration reached almost complete resolution within the set treatment-period of 10 days. Clinical tolerability of Nimesulide was better than that of Benzydamine: one case of moderate gastric pyrosis and drowsiness was complained of by the Nimesulide-treated patients versus eleven cases of gastro-intestinal discomfort, mouth dryness, and/or drowsiness which were complained of by the Benzydamine-treated patients.
 ...
PMID:Nimesulide for the treatment of painful inflammatory process in the ear, nose and throat areas: a double-blind controlled study with benzydamine. 651 48

The efficacy of nimesulide (100mg twice daily) was compared with that of naproxen (500mg twice daily) in 53 adult patients with nonbacterial acute inflammation of the ear, nose or throat in a double-blind phase III clinical investigation. Both drugs were administered orally after meals for a mean duration of 8.7 days. In this setting, nimesulide was associated with relief of pain and inflammatory signs (exudation and swelling). Indeed, treatment with nimesulide led to clinical improvement superior to that obtained with naproxen in terms of both rapidity of action and improvement of the symptoms at the end of therapy. Nimesulide therapy was also very well tolerated and no patient reported an adverse event. In contrast, 2 naproxen-treated patients reported episodic gastralgia of moderate intensity.
 ...
PMID:Nimesulide granules for the treatment of acute inflammation of the ear, nose or throat. 750 45

Nimesulide does not affect active intrauterine pressure, as measured using microsensors, or the direction and velocity of the propagation of uterine activity, but nevertheless alleviates pain significantly by 30 minutes after oral administration. In dysmenorrhoeic patients, resting pressure is high only in the fundus. Nimesulide reduces the pressure during the maximal but not during the submaximal pain period, with concomitant alleviation of pain. The drug changes the painful state of uterine contracture to painless cyclic contractions. With a single oral dose of 100mg, nimesulide is evenly distributed in female genital tissues (uterine fundus and cervix, oviduct and ovaries), reaching peak concentrations and peak plasma: tissue ratio (0.5) 3 hours after administration. Tissue concentrations range from 0.3 to 1.8 micrograms/g. Two 100mg oral doses of nimesulide administered to dysmenorrhoeic women in a double-blind placebo-controlled cross-over study reduced prostaglandin F2 alpha levels in menstrual blood from 382 to 94 micrograms/L. Double-blind placebo-controlled studies also confirmed that nimesulide relieves pain in dysmenorrhoeic patients.
 ...
PMID:Nimesulide in dysmenorrhoea. 750 51

The efficacy and tolerability of nimesulide were compared with those of ketoprofen when administered rectally in a double-blind investigation of 46 patients scheduled for dental surgery. Nimesulide was more effective and more rapid than ketoprofen in ameliorating the painful inflammatory symptoms (pain at rest and upon mastication) and signs (swelling and hyperaemia) associated with the operation. These effects were accompanied by improved quality of sleep and recovery of masticatory and swallowing function, which was superior for nimesulide-treated patients.
 ...
PMID:A double-blind comparison of nimesulide and ketoprofen in dental surgery. 750 62

The efficacy and tolerability profiles of nimesulide (a nonsteroidal anti-inflammatory drug) were assessed in 3 comparative double-blind clinical trials that each recruited 60 patients with osteoarthritis of the hip or knee. The duration of each investigation varied with the comparator agent chosen: 2 weeks for placebo; 3 weeks for piroxicam; 2 months for ketoprofen. Nimesulide and ketoprofen were each administered orally as a 100mg dose twice daily, while piroxicam was administered orally as a single daily 20mg dose. In each study the principal efficacy parameters were the improvement in spontaneous pain, assessed using a visual analogue scale, and the degree of functional impairment evaluated using the severity index of Lequesne; the final judgement of efficacy was made by the physician. In all studies, nimesulide improved these and other efficacy parameters with an activity significantly superior to that of placebo and comparable with that of reference drugs.
 ...
PMID:Nimesulide in the treatment of osteoarthritis. Double-blind studies in comparison with piroxicam, ketoprofen and placebo. 750 69

The efficacy and tolerability of nimesulide were compared with those of paracetamol in a nonblind randomised study that recruited 110 children (64 males, 46 females; aged 3 to 6 years) with inflammation of the upper respiratory tract and fever. Nimesulide suspension (1.5 mg/kg 3 times daily) or paracetamol syrup (10 mg/kg 4 times daily) were administered orally until fever resolved. Body temperature was recorded and local pain and general discomfort assessed. Three patients treated with nimesulide and 6 patients treated with paracetamol withdrew from the study as a result of adverse events, and 1 paracetamol-treated patient discontinued because of a requirement for therapy with steroids. Nimesulide was as effective as paracetamol in reducing fever, local pain, and general discomfort. Nimesulide therefore appears to be at least as effective as paracetamol in terms of antipyretic and anti-inflammatory activity in children with inflammation of the upper respiratory tract and fever.
 ...
PMID:A comparison of nimesulide and paracetamol in the treatment of fever due to inflammatory diseases of the upper respiratory tract in children. 750 80

As a primary objective, the safety profile of nimesulide was assessed in a nonblinded study that recruited 134 patients (aged 41 to 82 years) with osteoarthritis requiring long term treatment (> or = 1 year). Nimesulide (100mg orally twice daily) was well tolerated. No statistically significant differences were found between the number of patients of varying ages reporting adverse events. Moreover, most adverse experiences were found to be mild to moderate in intensity, with a prevalence of gastrointestinal disorders. The number of adverse episodes reported steadily decreased over the duration of the trial and no pathological changes in haematology and blood chemistry tests were found. Evaluation of efficacy revealed a progressive reduction in pain intensity with time.
 ...
PMID:Long term tolerability profile of nimesulide in the treatment of osteoarthritis. 750 88

Nimesulide is a nonsteroidal anti-inflammatory drug (NSAID) administered orally or rectally twice daily for a variety of inflammatory and pain states. In mostly short term studies (up to 4 weeks), it was effective in reducing pain associated with osteoarthritis, cancer, thrombophlebitis, oral surgery and dysmenorrhoea in adults, reducing pain associated with general surgery in adults and children, and pain, fever and inflammation accompanying respiratory tract infections, otorhinolaryngological diseases and traumatic injury in adults and children. Nimesulide appeared to be at least as effective as other NSAIDs in all of these indications. Nimesulide has been well tolerated by adult, elderly and paediatric patients in clinical trials and large postmarketing surveillance studies. In general qualitative terms nimesulide exhibits the usual adverse events associated with NSAIDs (gastrointestinal, dermatological and neurological). However, it has a pharmacodynamic profile suggestive of a possibly reduced propensity to cause adverse gastrointestinal effects, although this has not been conclusively demonstrated in comparative clinical trials, many of which showed a similar incidence of such effects for nimesulide and the comparator agent. Additionally, nimesulide has been well tolerated by most aspirin (acetylsalicylic acid)- and/or NSAID-intolerant patients and in patients with asthma. Thus, available evidence indicates that nimesulide is an effective and well tolerated alternative to other NSAIDs in the short term treatment of pain and inflammation of osteoarthritis and various other causes.
 ...
PMID:Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. 752 62

A parallel group study for one month of 392 patients was undertaken to define the optimal dose of nimesulide for the treatment of painful osteoarthritis (OA). By the final visit, the mean values for pain intensity for the nimesulide groups (50 mg, 100 mg and 200 mg bd) were similar and significantly lower than the mean for the placebo group. The onset of analgesia was rapid and continued throughout the 12-hour period after drug intake, a significant analgesic effect was demonstrated with nimesulide 100 mg and 200 mg within 1.5 hours. The patients' and the physicians' overall judgements of the drug efficacy demonstrated significant differences between the treatment groups with the most successful outcomes occurring with nimesulide 100 mg and 200 mg. Nimesulide 50 mg and 100 mg were generally well-tolerated but at the highest dose level, nimesulide 200 mg, the incidence of adverse events was greater although not significantly. Results of this study demonstrate nimesulide 100 mg twice daily to be the optimal dose for the treatment of OA.
 ...
PMID:Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. 774 32


<< Previous 1 2 3 4 5 Next >>